You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
NYAB Q3’24: Continued growth ahead
NYAB's Q3 numbers were below our expectations in terms of timing of revenue, but otherwise as expected. The order book is at a record level and the margin development continued positively.
Continued growth ahead! Analyst Aapeli Pursimo summarizes.
See the Q3 CEO-interview:
NYAB Q3´24: Strong order backlog
Read the latest research, published 11/7/2024:
NYAB Q3'24: Well positioned for future growth
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
GomSpace – Management Q&A
ExpreS2ion Biotech – A look back at 2024 with CEO
Vis alle videoer